Differential regulation of cardiac function and intracardiac cytokines by rapamycin in healthy and diabetic rats

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Luck, Christian ^a,b   Demarco, Vincent G ^a,b   Mahmood, Abuzar ^a,b   Gavini, Madhavi P ^c   Pulakat, Lakshmi ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Novopyxis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVITY; NETWORK SECURITY; RATS;

CARDIAC FUNCTIONS; CARDIO-VASCULAR DISEASE; DIFFERENTIAL REGULATION; IMMUNE RESPONSE; PATHWAY ANALYSIS; PROTEIN PROFILING; RAPAMYCIN TREATMENT; TARGET OF RAPAMYCIN;

HEART;

GAMMA INTERFERON; GLUCOSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INSULIN; INTERLEUKIN 10; MICRORNA; MICRORNA 208A; RAPAMYCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID; CYTOKINE; GLUCOSE BLOOD LEVEL; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC OBESITY; DIET RESTRICTION; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART TISSUE; HISTOPATHOLOGY; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNITY; MALE; NONHUMAN; RAT; REGULATORY MECHANISM; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; WESTERN BLOTTING; ANALYSIS; ANIMAL; BLOOD; CARDIAC MUSCLE; DIAGNOSTIC IMAGING; DRUG EFFECTS; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEART; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TIME FACTOR; ZUCKER RAT;

ANIMALS; DIAGNOSIS; DISEASES; MEDICINE;

ANIMALS; BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEART; INSULIN; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; MYOCARDIUM; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, ZUCKER; SIROLIMUS; TIME FACTORS; TRIGLYCERIDES; URIC ACID;

EID: 85017262753     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/5724046     Document Type: Article

References (64)

1. B. K. Kennedy and D.W. Lamming, "The mechanistic target of rapamycin: the grand ConducTOR of metabolism and aging, " Cell Metabolism, vol. 23, no. 6, pp. 990-1003, 2016.
2. T. Nacarelli and C. Sell, "Targeting metabolism in cellular senescence, a role for intervention, " Molecular and Cellular Endocrinology, 2016.
3. D. W. Lamming, "Inhibition of the mechanistic target of rapamycin (mTOR)-Rapamycin and beyond, " Cold Spring Harbor Perspectives in Medicine, vol. 6, no. 5, Article IDa025924, 2016.
4. S. Sengupta, T. R. Peterson, and D. M. Sabatini, "Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress, " Molecular Cell, vol. 40, no. 2, pp. 310-322, 2010.
5. R. Zoncu, A. Efeyan, and D. M. Sabatini, "MTOR: fromgrowth signal integration to cancer, diabetes and ageing, " Nature Reviews Molecular Cell Biology, vol. 12, no. 1, pp. 21-35, 2011.
6. R. D. Hannan, A. Jenkins, A. K. Jenkins, and Y. Brandenburger, "Cardiac hypertrophy: a matter of translation, " Clinical and Experimental Pharmacology and Physiology, vol. 30, no. 8, pp. 517-527, 2003.
7. R. Gul, V. G. DeMarco, J. R. Sowers, A. Whaley-Connell, and L. Pulakat, "Regulation of overnutrition-induced cardiac inflammatory mechanisms, " Cardiorenal Medicine, vol. 2, no. 3, pp. 225-233, 2012.
8. L. Pulakat, V. G. DeMarco, S. Ardhanari, et al., "Adaptivemechanisms to compensate for overnutrition-induced cardiovascular abnormalities, " American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 301, no. 4, pp. R885-R895, 2011.
9. R. Gul, A. Mahmood, C. Luck, et al., "Regulation of cardiac miR-208a, an inducer of obesity, by rapamycin and nebivolol, " Obesity, vol. 23, no. 11, pp. 2251-2259, 2015.
10. A. Perl, "mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging, " Annals of the New York Academy of Sciences, vol. 1346, no. 1, pp. 33-44, 2015.
11. D. E. Harrison, R. Strong, Z. D. Sharp, et al., "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice, " Nature, vol. 460, no. 7253, pp. 392-395, 2009.
12. R. A. Miller, D. E. Harrison, C. M. Astle, et al., "Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice, " Journals of Gerontology-Series A Biological Sciences andMedical Sciences, vol. 66, no. 2, pp. 191-201, 2011.
13. A. Salmon, "Beyond diabetes: does obesity-induced oxidative stress drive the aging process?" Antioxidants, vol. 5, no. 3, p. E24, 2016.
14. A. Das, D. Durrant, S. Koka, F. N. Salloum, L. Xi, and R. C. Kukreja, "Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression, " Journal of Biological Chemistry, vol. 289, no. 7, pp. 4145-4160, 2014.
15. A. Das, F. N. Salloum, S.M. Filippone, et al., "Inhibitionofmammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling, " Basic Research in Cardiology, vol. 110, no. 3, article 31, 2015.
16. K. Sataranatarajan, Y. Ikeno, A. Bokov, et al., "Rapamycin increases mortality in db/db mice, a mouse model of type 2 diabetes, " The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 71, no. 7, pp. 850-857, 2016.
17. N. Arnold, P. R. Koppula, R. Gul, C. Luck, and L. Pulakat, "Regulation of cardiac expression of the diabetic marker microRNA miR-29, " PLoS ONE, vol. 9, no. 7, Article ID e103284, 2014.
18. K. Dionne, R. L. Redfern, J. J. Nichols, et al., "Analysis of tear inflammatory mediators: a comparison between the microarray and luminex methods, " Molecular Vision, vol. 22, pp. 177-188, 2016.
19. Raybiotech, Quantibody Rat Cytokine Array 67.
20. H. Wickham, ggplot2: Elegant Graphics for Data Analysis, Springer, New York, NY, USA, 2009.
21. W.-M. Huang, P.-F. Hsu, H.-M. Cheng, et al., "Determinants and prognostic impact of hyperuricemia in hospitalization for acute heart failure, " Circulation Journal, vol. 80, no. 2, pp. 404-410, 2016.
22. A. Daniels, D. Linz, M. Van Bilsen, et al., "Long-Term severe diabetes only leads to mild cardiac diastolic dysfunction in Zucker diabetic fatty rats, " European Journal of Heart Failure, vol. 14, no. 2, pp. 193-201, 2012.
23. M. Ricke-Hoch, I. Bultmann, B. Stapel, et al., "Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress, " Cardiovascular Research, vol. 101, no. 4, pp. 587-596, 2014.
24. X.-G. Chen, F. Liu, X.-F. Song, et al., "Rapamycin regulates Akt and ERK phosphorylation throughmTORC1 andmTORC2 signaling pathways, "Molecular Carcinogenesis, vol. 49, no. 6, pp. 603-610, 2010.
25. B. W. Van Tassell, J. M. V. Raleigh, and A. Abbate, "Targeting interleukin-1 in heart failure and inflammatory heart disease, " Current Heart Failure Reports, vol. 12, no. 1, pp. 33-41, 2015.
26. H. B. Sager, T. Heidt, M. Hulsmans, et al., "Targeting interleukin-1 reduces leukocyte production after acute myocardial infarction, " Circulation, vol. 132, no. 20, pp. 1880-1890, 2015.
27. H. Peng, Z. Sarwar, X.-P. Yang, et al., "Profibrotic role for interleukin-4 in cardiac remodeling and dysfunction, " Hypertension, vol. 66, no. 3, pp. 582-589, 2015.
28. Z. Zeng, K. Yu, L. Chen, W. Li, H. Xiao, and Z. Huang, "Interleukin-2/anti-interleukin-2 immune complex attenuates cardiac remodeling after myocardial infarction through expansion of regulatory T cells, " Journal of Immunology Research, vol. 2016, Article ID 8493767, 13 pages, 2016.
29. S. P. Jones, S. D. Trocha, and D. J. Lefer, "Cardioprotective actions of endogenous IL-10 are independent of iNOS, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 281, no. 1, pp. H48-H52, 2001.
30. K. Kawamura, K. Iyonaga, H. Ichiyasu, J. Nagano, M. Suga, and Y. Sasaki, "Differentiation, maturation, and survival of dendritic cells by osteopontin regulation, " Clinical andDiagnostic Laboratory Immunology, vol. 12, no. 1, pp. 206-212, 2005.
31. A. M. Feldman, A. Combes, D. Wagner, et al., "Therole of tumor necrosis factor in the pathophysiology of heart failure, " Journal of the American College of Cardiology, vol. 35, no. 3, pp. 537-544, 2000.
32. D. S. Cross, C. A. McCarty, E. Hytopoulos, et al., "Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts, " CurrentMedical Research andOpinion, vol. 28, no. 11, pp. 1819-1830, 2012.
33. J. J. Carrero, J. Kyriazis, A. Sonmez, et al., "Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD, " Clinical Journal of the American Society of Nephrology, vol. 7, no. 2, pp. 207-215, 2012.
34. A. Boufenzer, J. Lemarié, T. Simon, et al., "TREM-1 mediates inflammatory injury and cardiac remodeling followingmyocardial infarction, " Circulation Research, vol. 116, no. 11, pp. 1772-1782, 2015.
35. I. Kogan-Sakin, M. Cohen, N. Paland, et al., "Prostate stromal cells produceCXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1, " Carcinogenesis, vol. 30, no. 4, pp. 698-705, 2009.
36. M. Tomaszewski, F. J. Charchar, C. P. Nelson, et al., "Pathway analysis shows association between FGFBP1 and hypertension, " Journal of the American Society of Nephrology, vol. 22, no. 5, pp. 947-955, 2011.
37. J. Jahanyar, D. L. Joyce, R. E. Southard, et al., "Decorinmediated transforming growth factor- inhibition ameliorates adverse cardiac remodeling, " The Journal of Heart and Lung Transplantation, vol. 26, no. 1, pp. 34-40, 2007.
38. Y. Wang, Y. Cao, S. Yamada, et al., "Cardiomyopathy and Worsened Ischemic Heart Failure in SM22- Cre-Mediated Neuropilin-1 Null Mice: Dysregulation of PGC1 and Mitochondrial Homeostasis, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 6, pp. 1401-1412, 2015.
39. J. C. Schisler, R. Schuck, X. Dai, et al., "Clinical evidence of a protective role for CXCL5 in coronary artery disease progression in the elderly, " The FASEB Journal, vol. 30, no. 1, supplement 1177.17, 2016.
40. S. P. Levick and P. H. Goldspink, "Could interferon-gamma be a therapeutic Target for treating heart failure?" Heart Failure Reviews, vol. 19, no. 2, pp. 227-236, 2014.
41. G. F. Pierce, J. E. Tarpley, J. Tseng, et al., "Detection of plateletderived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds, " Journal of Clinical Investigation, vol. 96, no. 3, pp. 1336-1350, 1995.
42. B. McCright, J. Lozier, and T. Gridley, "A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency, " Development, vol. 129, no. 4, pp. 1075-1082, 2002.
43. H. Jin, J. M. Wyss, R. Yang, and R. Schwall, "The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure, " Current Pharmaceutical Design, vol. 10, no. 20, pp. 2525-2533, 2004.
44. M. F. Brizzi, L. Formato, P. Dentelli, et al., "Interleukin-3 stimulates migration and proliferation of vascular smooth muscle cells: a potential role in atherogenesis, " Circulation, vol. 103, no. 4, pp. 549-554, 2001.
45. A. Q. Reuwer, M. T. B. Twickler, B. A. Hutten, et al., "Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women, " Circulation: Cardiovascular Genetics, vol. 2, no. 4, pp. 389-395, 2009.
46. A. Wilhelm, E. L. Shepherd, A. Amatucci, et al., "Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation, " Journal of Pathology, vol. 239, no. 1, pp. 109-121, 2016.
47. X. Shi, M. Zhang, F. Liu, et al., "Tim-1-Fc suppresses chronic cardiac allograft rejection and vasculopathy by reducing IL-17 production, " International Journal of Clinical and Experimental Pathology, vol. 7, no. 2, pp. 509-520, 2014.
48. R. Spagnuolo, M. Corada, F. Orsenigo, et al., "Gas1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis, " Blood, vol. 103, no. 8, pp. 3005-3012, 2004.
49. S. I. Arriola Apelo, J. C. Neuman, E. L. Baar, et al., "Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system, " Aging Cell, vol. 15, no. 1, pp. 28-38, 2016.
50. J. M. Flynn, M. N. O'Leary, C. A. Zambataro, et al., "Late-life rapamycin treatment reverses age-related heart dysfunction, " Aging Cell, vol. 12, no. 5, pp. 851-862, 2013.
51. R. F. Mapanga and M. F. Essop, "Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways, " American Journal of Physiology-Heart and Circulatory Physiology, vol. 310, no. 2, pp. H153-H173, 2016.
52. J. Shi, J. Li, H. Guan, et al., "Anti-fibrotic actions of interleukin-10 against hypertrophic scarring by activation of PI3K/AKT and STAT3 signaling pathways in scar-forming fibroblasts, " PLoS ONE, vol. 9, no. 5, article e98228, 2014.
53. J. Shi, J. Li, H. Guan, et al., "Anti-fibrotic actions of interleukin-10 against hypertrophic scarring by activation of PI3K/AKT and STAT3 signaling pathways in scar-forming fibroblasts, " PLoS ONE, vol. 9, no. 5, Article ID e98228, 2014.
54. M. S. Wilson, E. Elnekave, M. M. Mentink-Kane, et al., "IL-13R2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice, " Journal of Clinical Investigation, vol. 117, no. 10, pp. 2941-2951, 2007.
55. S. D. Oldroyd, G. L. Thomas, G. Gabbiani, and A. Meguid El Nahas, "Interferon- inhibits experimental renal fibrosis, " Kidney International, vol. 56, no. 6, pp. 2116-2127, 1999.
56. H. Emmez, O. Kardes, F. Dogulu, G. Kurt, L. Memis, and M. K. Baykaner, "Role of antifibrotic cytokine interferon- in the prevention of postlaminectomy peridural fibrosis in rats, " Neurosurgery, vol. 62, no. 6, pp. 1351-1357, 2008.
57. B. B. Moore, M. J. Coffey, P. Christensen, et al., "GMCSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism, " Journal of Immunology, vol. 165, no. 7, pp. 4032-4039, 2000.
58. F. Chirillo, F. Bacchion, A. Pedrocco, et al., "Infective endocarditis in patients with diabetes mellitus, " Journal of Heart Valve Disease, vol. 19, no. 3, pp. 312-320, 2010.
59. L. M. A. J. Muller, K. J. Gorter, E. Hak, et al., "Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus, " Clinical Infectious Diseases, vol. 41, no. 3, pp. 281-288, 2005.
60. M. L. Davila, Y. Fu, J. Yang, et al., "Role of CCR10 and CCL27 in skin resident T cell development and homeostasis, " The Journal of Immunology, vol. 196, no. 1, supplement, p. 137.7, 2016.
61. C. Yang, B. Chen, J. Zhao, et al., "TREM-1 signaling promotes host defense during the early stage of infection with highly pathogenic Streptococcus suis, " Infection and Immunity, vol. 83, no. 8, pp. 3293-3301, 2015.
62. J. A. Suaya, D. F. Eisenberg, C. Fang, and L. G. Miller, "Skin and soft tissue infections and associated complications among commercially insured patients aged 0-64 years with and without diabetes in the U.S, " PLoS ONE, vol. 8, no. 4, Article ID e60057, 2013.
63. N. Gude and M. Sussman, "Notch signaling and cardiac repair, " Journal of Molecular and Cellular Cardiology, vol. 52, no. 6, pp. 1226-1232, 2012.
64. A. Mahmood and L. Pulakat, "Differential effects of -blockers, Angiotensin II receptor blockers, and a novel AT2R agonist NP-6A4 on stress response of nutrient-starved cardiovascular cells, " PLoS ONE, vol. 10, no. 12, Article ID e0144824, 2015.